Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine in STN-DBS for Parkinson's Disease
NCT06543563Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of esketamine in Parkinson's disease (PD) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Normalized Root Mean Square at 1 day. Started Aug 2024; status: recruiting.
02
Drugs
esketamine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06543563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06543563.